Patients’ and healthcare providers’ views regarding dose reduction of tyrosine kinase inhibitors in chronic myeloid leukemia: a qualitative study

Patients and healthcare providers have positive views on TKI dose reduction to improve the burden of CML treatment. Acceptance is shaped by their beliefs and concerns, while successful implementation depends on addressing practical needs and shared-decision making.